These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27477652)

  • 21. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
    Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
    Xie R; Li Y; Tang P; Yuan Q
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
    Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
    Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
    Sharma S; Ahmad M; Bhat JA; Kumar A; Kumar M; Zargar MA; Hamid A; Shah BA
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4729-4734. PubMed ID: 25176189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
    Stenzel K; Hamacher A; Hansen FK; Gertzen CGW; Senger J; Marquardt V; Marek L; Marek M; Romier C; Remke M; Jung M; Gohlke H; Kassack MU; Kurz T
    J Med Chem; 2017 Jul; 60(13):5334-5348. PubMed ID: 28581289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of Santacruzamate-A based analogues.
    Randino R; Gazzerro P; Mazitschek R; Rodriquez M
    Bioorg Med Chem; 2017 Dec; 25(24):6486-6491. PubMed ID: 29100734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
    Cincinelli R; Zwick V; Musso L; Zuco V; De Cesare M; Zunino F; Simoes-Pires C; Nurisso A; Giannini G; Cuendet M; Dallavalle S
    Eur J Med Chem; 2016 Apr; 112():99-105. PubMed ID: 26890116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.